Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia
AssigneeMemorial Sloan Kettering Cancer Center
InventorScott A. Armstrong
Life of this patent
Estimating the term…
Abstract
Disclosed are methods for inhibiting proliferation of or inducing apoptosis in certain leukemia cells or both. The methods comprise contacting a leukemia cell exhibiting an NPM1 mutation with a pharmacologic inhibitor of interaction between MLL and menin. More broadly, disclosed are methods for treating a susceptible leukemia using pharmacologic inhibition of Menin-MLL interaction. Also disclosed are methods for treating such leukemias using inhibition of Menin-MLL interaction in combination with DOT1L inhibition.
Claims13
A method for inhibiting proliferation and/or inducing apoptosis in a leukemia cell, comprising contacting the leukemia cell with an inhibitor of interaction between MLL and menin, wherein the leukemia cell exhibits an NPM1 mutation, and does not exhibit a genetic mutation, alteration, and/or abnormality that is an MLL-translocation (MLL-t), an MLL-rearrangement (MLL-r), or an MLL-partial tandem duplication (MLL-PTD).
A method for treating leukemia in a patient in need thereof, comprising:
- administering to the patient an effective amount of an inhibitor of interaction between MLL and menin;
- wherein the patient exhibits an NPM1 mutation, and does not exhibit a genetic mutation, alteration, and/or abnormality selected from the group consisting of an MLL-t, an MLL-r, and an MLL-PTD.
Dependencies are inferred from the claim text.